BrainsWay Stock Forecast, Price & News

-0.02 (-0.22 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume280 shs
Average Volume65,741 shs
Market Capitalization$147.39 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BrainsWay logo

About BrainsWay

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

690th out of 2,221 stocks

Surgical & Medical Instruments Industry

77th out of 185 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BrainsWay (NASDAQ:BWAY) Frequently Asked Questions

Is BrainsWay a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BrainsWay stock.
View analyst ratings for BrainsWay
or view top-rated stocks.

What stocks does MarketBeat like better than BrainsWay?

Wall Street analysts have given BrainsWay a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BrainsWay wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BrainsWay?

BrainsWay saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 51,700 shares, a decrease of 13.4% from the June 30th total of 59,700 shares. Based on an average daily trading volume, of 54,400 shares, the short-interest ratio is presently 1.0 days.
View BrainsWay's Short Interest

When is BrainsWay's next earnings date?

BrainsWay is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for BrainsWay

How can I listen to BrainsWay's earnings call?

BrainsWay will be holding an earnings conference call on Wednesday, August 11th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were BrainsWay's earnings last quarter?

BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings data on Thursday, May, 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The firm had revenue of $6.12 million for the quarter, compared to analyst estimates of $5.80 million. BrainsWay had a negative net margin of 19.44% and a negative trailing twelve-month return on equity of 15.38%.
View BrainsWay's earnings history

How has BrainsWay's stock price been impacted by COVID-19?

BrainsWay's stock was trading at $8.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BWAY stock has increased by 9.4% and is now trading at $8.96.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BWAY?

5 brokers have issued 1-year price targets for BrainsWay's stock. Their forecasts range from $12.00 to $17.00. On average, they anticipate BrainsWay's stock price to reach $14.40 in the next year. This suggests a possible upside of 60.7% from the stock's current price.
View analysts' price targets for BrainsWay
or view top-rated stocks among Wall Street analysts.

Who are BrainsWay's key executives?

BrainsWay's management team includes the following people:
  • Dr. Christopher R. von Jako Ph.D., Pres & CEO (Age 52, Pay $463.75k)
  • Mr. Christopher J. Boyer Ph.D., VP of Global Marketing (Age 43, Pay $146.67k)
  • Mr. Hadar Levy, Sr. VP & GM of North America (Age 47, Pay $354k)
  • Dr. David Zacut, Founder & Chairman (Age 68)
  • Mr. Avner Hagai, Founder & Independent Vice-Chairman (Age 65)
  • Prof. Abraham Zangen, Co-Founder, Member of Scientific Advisory Board & Director (Age 51)
  • Dr. Yiftach Roth, Founder & Chief Scientific Officer (Age 50)
  • Mr. Richard Scott Areglado, Sr. VP & CFO (Age 57)
  • Mr. Menachem C. Klein Esq., VP, Gen. Counsel & Corp. Sec.
  • Dr. Aron Tendler, Chief Medical Officer

Who are some of BrainsWay's key competitors?

What other stocks do shareholders of BrainsWay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

When did BrainsWay IPO?

(BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor served as the underwriter for the IPO.

What is BrainsWay's stock symbol?

BrainsWay trades on the NASDAQ under the ticker symbol "BWAY."

Who are BrainsWay's major shareholders?

BrainsWay's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (1.25%).

Which institutional investors are buying BrainsWay stock?

BWAY stock was bought by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC.

How do I buy shares of BrainsWay?

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BrainsWay's stock price today?

One share of BWAY stock can currently be purchased for approximately $8.96.

How much money does BrainsWay make?

BrainsWay has a market capitalization of $147.39 million and generates $22.06 million in revenue each year. The company earns $-5,390,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does BrainsWay have?

BrainsWay employs 100 workers across the globe.

What is BrainsWay's official website?

The official website for BrainsWay is

Where are BrainsWay's headquarters?

BrainsWay is headquartered at 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518.

How can I contact BrainsWay?

BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at (722) 581-3140 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.